» Articles » PMID: 39091838

Systematic Multi-Omics Investigation of Androgen Receptor Driven Gene Expression and Epigenetics Changes in Prostate Cancer

Overview
Journal bioRxiv
Date 2024 Aug 2
PMID 39091838
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Prostate cancer, a common malignancy, is driven by androgen receptor (AR) signaling. Understanding the function of AR signaling is critical for prostate cancer research.

Methods: We performed multi-omics data analysis for the AR, androgen-sensitive LNCaP cell line, focusing on gene expression (RNAseq), chromatin accessibility (ATACseq), and transcription factor binding (ChIPseq). High-quality datasets were curated from public repositories and processed using state-of-the-art bioinformatics tools.

Results: Our analysis identified 1004 up-regulated and 707 down-regulated genes in response to androgen deprivation therapy (ADT) which diminished AR signaling activity. Gene-set enrichment analysis revealed that AR signaling influences pathways related to neuron differentiation, cell adhesion, P53 signaling, and inflammation. ATACseq and ChIPseq data demonstrated that as a transcription factor, AR primarily binds to distal enhancers, influencing chromatin modifications without affecting proximal promoter regions. In addition, the AR-induced genes maintained higher active chromatin states than AR-inhibited genes, even under ADT conditions. Furthermore, ADT did not directly induce neuroendocrine differentiation in LNCaP cells, suggesting a complex mechanism behind neuroendocrine prostate cancer development. In addition, a publicly available online application LNCaP-ADT (https://pcatools.shinyapps.io/shinyADT/) was launched for users to visualize and browse data generated by this study.

Conclusion: This study provides a comprehensive multi-omics dataset, elucidating the role of AR signaling in prostate cancer at the transcriptomic and epigenomic levels. The reprocessed data is publicly available, offering a valuable resource for future prostate cancer research.

References
1.
Wang Z, Zang C, Rosenfeld J, Schones D, Barski A, Cuddapah S . Combinatorial patterns of histone acetylations and methylations in the human genome. Nat Genet. 2008; 40(7):897-903. PMC: 2769248. DOI: 10.1038/ng.154. View

2.
Sadi M, Walsh P, Barrack E . Immunohistochemical study of androgen receptors in metastatic prostate cancer. Comparison of receptor content and response to hormonal therapy. Cancer. 1991; 67(12):3057-64. DOI: 10.1002/1097-0142(19910615)67:12<3057::aid-cncr2820671221>3.0.co;2-s. View

3.
Gao N, Ishii K, Mirosevich J, Kuwajima S, Oppenheimer S, Roberts R . Forkhead box A1 regulates prostate ductal morphogenesis and promotes epithelial cell maturation. Development. 2005; 132(15):3431-43. DOI: 10.1242/dev.01917. View

4.
Rada-Iglesias A, Bajpai R, Swigut T, Brugmann S, Flynn R, Wysocka J . A unique chromatin signature uncovers early developmental enhancers in humans. Nature. 2010; 470(7333):279-83. PMC: 4445674. DOI: 10.1038/nature09692. View

5.
Han W, Liu M, Han D, Toure A, Li M, Besschetnova A . Exploiting the tumor-suppressive activity of the androgen receptor by CDK4/6 inhibition in castration-resistant prostate cancer. Mol Ther. 2022; 30(4):1628-1644. PMC: 9077383. DOI: 10.1016/j.ymthe.2022.01.039. View